Q-med's report for the first nine months of 1998

Q-MED'S REPORT FOR THE FIRST NINE MONTHS OF 1998 * Revenues increased by 106% to SEK 59.0 million. * Income after financial items amounted to SEK 13.5 (2.6) million. * Restylane® approved for the Brazilian market. Revenues and income Q-Med continues to grow at a rapid rate and the Group reports revenues of SEK 59.0 (28.7) million for the first nine months of 1998. The majority of these revenues are accounted for by Restylane®, Q-Med's product for filling out lips, facial wrinkles and facial folds. Restylane's distribution network has been extended and now covers all of Europe as well as Australia/New Zealand. In March subsidiaries were also started in USA and Canada and from September the dormant subsidiary in England has been reactivated. Restylane was approved for registration in Canada at the end of June and in Brazil in the middle of September. The registration process has also been initiated in Japan. Operating income for the period amounted to SEK 14.3 (2.8) million. Amortization and depreciation of SEK 1.9 (0.9) million have been charged against income, of which SEK 0.5 (-) million was amortization of goodwill. Income after financial items amounted to SEK 13.5 (2.6) million. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1998/09/28/19991115BIT00340/bit0001.doc http://www.bit.se/bitonline/1998/09/28/19991115BIT00340/bit0002.pdf